Role of Brusatol in Preventing Gastrointestinal Cancer: Recent Trends and Future Perspectives

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Gastrointestinal (GI) cancers pose a significant global health challenge, characterized by high incidence and mortality rates.
• Brusatol, a natural compound, demonstrates potent anticancer activity against various malignancies.
• Its therapeutic potential is linked to the inhibition of the nuclear factor erythroid 2-related factor 2 (NRF2) signaling pathway.

Purpose of the Study:

• To review the molecular mechanisms underlying brusatol's efficacy in GI cancers.
• To explore the synergistic potential of brusatol with conventional treatments and advanced delivery systems.
• To identify future research directions for developing safer and more selective brusatol derivatives.

Main Methods:

• Literature review of studies on brusatol's anticancer mechanisms in GI cancers.
• Analysis of brusatol's effects on NRF2 signaling, redox balance, and cellular stress responses.
• Evaluation of synergistic effects with chemotherapy and potential of nanotechnology-based delivery.

Main Results:

• Brusatol inhibits the NRF2 pathway, modulates redox homeostasis, and sensitizes cancer cells to oxidative stress and chemotherapy.
• Evidence suggests synergistic potential when combined with existing therapeutic strategies.
• Nanotechnology offers promising avenues for targeted brusatol delivery.

Conclusions:

• Brusatol exhibits significant potential as a therapeutic agent for GI cancers through multiple molecular mechanisms.
• Combination therapies and novel delivery systems may enhance its clinical efficacy.
• Development of optimized brusatol derivatives is crucial for advancing GI cancer treatment.